Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach

Table 3 Treatment outcomes in patients with each sequential chemotherapy

	FFX-GnP (n = 120)	GnP-FFX (n = 61)	P value	FFX-GnP (n = 53)	GnP-FFX (n = 59)	P value
Treatment duration (months)	12.0 (7.6–18.1)	11.7 (7.6–19.4)	0.945	12.0 (8.0–22.3)	11.7 (7.4–20.0)	0.714
Best response in second-line treatment			0.86			0.69
CR	1 (0.8)	0 (0)		1 (1.9)	0 (0)
PR	19 (15.8)	10 (16.4)		7 (13.2)	10 (16.9)
SD	61 (50.8)	29 (47.5)		27 (50.9)	28 (47.5)
PD	39 (32.5)	22 (36.1)		18 (34.0)	21 (35.6)
Response rates in second-line treatment
DCR	81 (67.5)	39 (63.9)	0.631	35 (66.0)	38 (64.4)	0.86
ORR	20 (16.7)	10 (16.4)	0.963	8 (15.1)	10 (16.9)	0.79
Third-line chemotherapy	47 (39.2)	29 (47.5)	0.508	16 (30.2)	28 (47.5)	0.14
Other 5-FU^a	46	6		1	6
Other gemcitabine^b	1	21		15	20
Other (clinical trial, SBRT)	0	2		0	2

FFX FOLFIRINOX, GnP gemcitabine plus nab-paclitaxel, AEs adverse events, CR complete response, PR partial response, SD stable disease, PD progression of disease, ORR objective response rate, DCR disease control rate, 5-FU 5-fluorouracil, SBRT stereotactic body radiotherapy, NAPOLI nanoliposomal irinotecan plus 5-FU/lecovorin, iFAM infusional 5-FU plus doxorubicin and mitomycin-C
^aIncluded the NAPOLI, iFAM, tegafur/gimestat/otastat potassium, capecitabine, and CCRT with 5-FU or capecitabine regimens
^bIncluded gemcitabine, gemcitabine plus erlotinib

ISSN: 1471-2407